Presa Jessica, Carrico Ruth, Fergie Jaime E, Hanenberg Stephanie, Marshall Gary S, Rivard Kaitlyn, Shaw Jana, Zimet Gregory D, Peyrani Paula, Cane Alejandro
Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA.
Division of Infectious Diseases, University of Louisville, Louisville, KY, USA.
Infect Dis Ther. 2025 Jun 3. doi: 10.1007/s40121-025-01166-7.
In 2022, experts convened under the name Advancing Strategies to Prevent Meningococcal Disease (ARTEMIS) to gather insights on issues related to invasive meningococcal disease (IMD) and meningococcal vaccination in the US. Discussions regarding successes, challenges, and future directions for the US meningococcal vaccination program are summarized. Current vaccination recommendations target adolescents/young adults (AYA), who are at increased risk of IMD. Suboptimal vaccination rates, particularly for meningococcal serogroup B disease, may stem from gaps in knowledge surrounding IMD and meningococcal vaccination among healthcare providers (HCPs), parents, and AYA; confusion among HCPs regarding the shared clinical decision-making recommendation for serogroup B vaccinations; demographic variables; and lack of preventive healthcare visits. ARTEMIS proposed strategies to address knowledge gaps and access barriers at the HCP, parent/AYA, and educational institution/policymaker levels. Alternative vaccination schedules using a recently approved MenABCWY vaccine that provides protection against all five major serogroups may simplify meningococcal vaccination and increase coverage.
2022年，专家们以“推进预防脑膜炎球菌病战略”（ARTEMIS）的名义召开会议，以收集有关美国侵袭性脑膜炎球菌病（IMD）和脑膜炎球菌疫苗接种相关问题的见解。会议总结了关于美国脑膜炎球菌疫苗接种计划的成功经验、挑战和未来方向。目前的疫苗接种建议针对IMD风险增加的青少年/青年（AYA）。疫苗接种率不理想，尤其是B群脑膜炎球菌病的接种率，可能源于医疗保健提供者（HCP）、父母和AYA对IMD和脑膜炎球菌疫苗接种的知识差距；HCP对B群疫苗接种的共同临床决策建议存在困惑；人口统计学变量；以及缺乏预防性医疗就诊。ARTEMIS提出了在HCP、父母/AYA以及教育机构/政策制定者层面解决知识差距和获取障碍的策略。使用最近批准的可预防所有五个主要血清群的MenABCWY疫苗的替代疫苗接种时间表可能会简化脑膜炎球菌疫苗接种并提高覆盖率。
